Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy

Trends in Pharmacological Sciences

Volumn 28, Issue 1, 2007, Pages 6-13

  Konstantinopoulos, Panagiotis A ^a,b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; ALENDRONIC ACID; ANTINEOPLASTON AS2-1; AZD 3409; BISPHOSPHONIC ACID DERIVATIVE; ENZYME; FLUINDOSTATIN; GGTI 297; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; L 778123; MEVALONIC ACID; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BIOSYNTHESIS; BONE CANCER; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MYALGIA; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MEVALONIC ACID; NEOPLASMS; PROTEIN ISOPRENYLATION;

EID: 33845944650     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.11.005     Document Type: Article

References (45)

1. Houten S.M., et al. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell. Mol. Life Sci. 60 (2003) 1118-1134
2. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65 (1996) 241-269
3. Ashby M.N. CaaX converting enzymes. Curr. Opin. Lipidol. 9 (1998) 99-102
4. Sahai E., and Marshall C.J. RHO-GTPases and cancer. Nat. Rev. Cancer 2 (2002) 133-142
5. Hutchison C.J. Lamins: building blocks or regulators of gene expression?. Nat. Rev. Mol. Cell Biol. 3 (2002) 848-858
6. Winter-Vann A.M., and Casey P.J. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 5 (2005) 405-412
7. Appels N.M., et al. Development of farnesyl transferase inhibitors: a review. Oncologist 10 (2005) 565-578
8. Peterson Y.K., et al. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J. Biol. Chem. 281 (2006) 12445-12450
9. Kusama T., et al. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res. 61 (2001) 4885-4891
10. Mo H., and Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp. Biol. Med. (Maywood) 229 (2004) 567-585
11. Hindler K., et al. The role of statins in cancer therapy. Oncologist 11 (2006) 306-315
12. Goldstein J.L., et al. Regulation of the mevalonate pathway. Nature 343 (1990) 425-430
13. Elson C.E., et al. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc. Soc. Exp. Biol. Med. 221 (1999) 294-311
14. Buckner J.C., et al. Phase II study of antineoplastons A10 (NSC 648539) and AS2-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin. Proc. 74 (1999) 137-145
15. Harrison L.E., et al. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery 124 (1998) 541-550
16. van Beek E., et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem. Biophys. Res. Commun. 255 (1999) 491-494
17. Alakangas A., et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif. Tissue Int. 70 (2002) 40-47
18. Green J.R. Bisphosphonates: preclinical review. Oncologist 9 (2004) 3-13
19. Sebti S.M. Protein farnesylation: implications for normal physiology, malignant transformation, and cancer therapy. Cancer Cell 7 (2005) 297-300
20. Lackner M.R. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell 7 (2005) 325-336
21. Rao S., et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. 22 (2004) 3950-3957
22. Mcdonald J.S., et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs 23 (2005) 485-487
23. Zimmerman T.M., et al. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J. Clin. Oncol. 22 (2004) 4816-4822
24. Whyte D.B., et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272 (1997) 14459-14464
25. Omer C.A. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. 60 (2000) 2680-2688
26. Mijimolle N., et al. Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development. Cancer Cell 7 (2005) 313-324
27. Du W., et al. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19 (1999) 1831-1840
28. Winter-Vann A.M., et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 4336-4341
29. Bergo M.O., et al. Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. Mol. Cell. Biol. 22 (2002) 171-181
30. Bergo M.O., et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J. Clin. Invest. 113 (2004) 539-550
31. Clarke S., et al. Fighting cancer by disrupting C-terminal methylation of signaling proteins. J. Clin. Invest. 113 (2004) 513-515
32. Chiu V.K., et al. Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4 (2002) 343-350
33. Morgan M.A. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br. J. Haematol. 130 (2005) 912-925
34. Lobell R.B., et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61 (2001) 8758-8768
35. Sun J., et al. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16 (1998) 1467-1473
36. Reid T.S., et al. Crystallographic analysis reveals that anticancer clinical candidate L-778,123 inhibits protein farnesyltransferase and geranylgeranyltransferase-I by different binding modes. Biochemistry 43 (2004) 9000-9008
37. Lobell R.B., et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol. Cancer Ther. 1 (2002) 747-758
38. Kelly J., et al. The prenyltransferase inhibitor AZD3409 has anti-tumor activity in preclinical models of urothelial carcinoma. Proc. Am. Assoc. Cancer Res. 46 (2005) 5962
39. Budman D.R., and Calabro A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 70 (2006) 147-153
40. Andela V.B. Synergism of aminobisphosphonates and farnesyl transferase inhibitors on tumor metastasis. Clin. Orthop. Relat. Res. 397 (2002) 228-239
41. Demierre M., et al. Statins and cancer prevention. Nat. Rev. Cancer 5 (2005) 930-942
42. Vincenzi B., et al. Statins may potentiate bisphosphonates anticancer properties: a new pharmacological approach?. Med. Hypotheses 61 (2003) 98-101
43. Caraglia M., et al. Emerging anti-cancer molecular mechanism of aminobisphosphonates. Endocr. Relat. Cancer 13 (2006) 7-26
44. McCarty M.F., et al. Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med. Hypotheses 56 (2001) 12-16
45. Michaelson D., et al. Postprenylation CAAX processing is required for proper localization of Ras but not Rho GTPases. Mol. Biol. Cell 16 (2005) 1606-1616